Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis

NCT02468791 is registered in ClinicalTrials.gov with Mabion SA as lead sponsor.

NCT NCT02468791
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02468791 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis
Lead sponsor
Mabion SA
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2013
Completion date
October 31, 2017
Enrollment
709 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis